From cirrhosis to hepatocellular carcinoma in HCV-infected patients: genes involved in tumor progression
Y. Wang, J. Li*, J. Chen, L. Liu, Z. Peng, J. Ding, K. Ding Department of Interventional Radiology, Fengxian Center Hospital, Shanghai, China. lijinzhang0320@hotmail.com *Emergency Department of Fengxian Center Hospital, Shanghai, China
BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive tumor with poor prognosis. Understanding molecular changes in hepatocellular carcinoma should improve identification of risk factors in molecular subtypes and provide potential targets for early detection and therapy.
AIM: The present study aimed to analyze the molecular mechanism of the transition from hepatitis C virus (HCV) induced cirrhosis to HCV induced HCC using microarray analysis combined with bioinformatics techniques.
METHODS: To accomplish this, we performed the differential coexpression analysis of hepatic gene expression in samples of HCV-cirrhotic patients with and without HCC. Total 465 genes were identified and some of them were used to construct a regulatory network.
RESULTS: Our analysis indicated that several differentially co-express genes might play crucial roles in HCC development, including NA3C2, AHR, MYC, FOXO1 and FOSB. Further analysis predicted these genes might be involved in HCC through pathways of “ribosome”, “steroid biosynthesis”, “spliceosome” and so on. Moreover, these genes may serve as potential therapeutic targets for the treatment of HCC.
CONCLUSIONS: In conclusion, our findings confirm the presence of multiple molecular alterations during HCV-infected HCC hepatocarcinogenesis and indicate the possibility for identifying prognostic factors associated with HCC progression.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
Y. Wang, J. Li*, J. Chen, L. Liu, Z. Peng, J. Ding, K. Ding
From cirrhosis to hepatocellular carcinoma in HCV-infected patients: genes involved in tumor progression
Eur Rev Med Pharmacol Sci
Year: 2012
Vol. 16 - N. 8
Pages: 995-1000